Use of a Scalable Replicon-Particle Vaccine to Protect Against Lethal Lassa Virus Infection in the Guinea Pig Model

No abstract is available for this paper.

• Publication year

  2018

• Venue

  Journal of Infectious Diseases

• Publication date

  2018-05-25

• Fields of study

  Biology, Medicine, Environmental Science

• Identifiers
  DOI 10.1093/infdis/jiy123PMID 29800368PMCID PMC6086598
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Development of live-attenuated arenavirus vaccines based on codon deoptimization of the viral glycoprotein.

  2017cited by this paper
• Temporal Progression of Lesions in Guinea Pigs Infected With Lassa Virus

  2017cited by this paper
• A DNA vaccine delivered by dermal electroporation fully protects cynomolgus macaques against Lassa fever

  2017cited by this paper
• An Ebola whole-virus vaccine is protective in nonhuman primates

  2015cited by this paper
• A Recombinant Vesicular Stomatitis Virus-Based Lassa Fever Vaccine Protects Guinea Pigs and Macaques against Challenge with Geographically and Genetically Distinct Lassa Viruses

  2015cited by this paper
• The Z Proteins of Pathogenic but Not Nonpathogenic Arenaviruses Inhibit RIG-i-Like Receptor-Dependent Interferon Production

  2014cited by this paper
• The Genome Landscape of the African Green Monkey Kidney-Derived Vero Cell Line

  2014cited by this paper
• Enhanced Efficacy of a Codon-Optimized DNA Vaccine Encoding the Glycoprotein Precursor Gene of Lassa Virus in a Guinea Pig Disease Model When Delivered by Dermal Electroporation

  2013cited by this paper
• Lassa Fever in West Africa: Evidence for an Expanded Region of Endemicity

  2012cited by this paper
• Single-Dose Immunization with Virus Replicon Particles Confers Rapid Robust Protection against Rift Valley Fever Virus Challenge

  2012cited by this paper
• Efficient Rescue of Recombinant Lassa Virus Reveals the Influence of S Segment Noncoding Regions on Virus Replication and Virulence

  2011cited by this paper
• Creation of a Nonspreading Rift Valley Fever Virus

  2011cited by this paper
• Evaluation of Lassa antiviral compound ST-193 in a guinea pig model

  2011cited by this paper
• Lassa Virus Nucleoprotein Mutants Generated by Reverse Genetics Induce a Robust Type I Interferon Response in Human Dendritic Cells and Macrophages

  2011cited by this paper
• Structure of the Lassa virus nucleoprotein reveals a dsRNA-specific 3′ to 5′ exonuclease activity essential for immune suppression

  2011cited by this paper
• Cap binding and immune evasion revealed by Lassa nucleoprotein structure

  2010cited by this paper
• Lassa virus-like particles displaying all major immunological determinants as a vaccine candidate for Lassa hemorrhagic fever

  2010cited by this paper
• Z Proteins of New World Arenaviruses Bind RIG-I and Interfere with Type I Interferon Induction

  2009cited by this paper
• Replication-Deficient Ebolavirus as a Vaccine Candidate

  2009cited by this paper
• Safety, immunogenicity, and efficacy of the ML29 reassortant vaccine for Lassa fever in small non-human primates.

  2008cited by this paper
• Differential Inhibition of Type I Interferon Induction by Arenavirus Nucleoproteins

  2007cited by this paper
• Old World arenavirus infection interferes with the expression of functional alpha-dystroglycan in the host cell.

  2007cited by this paper
• A recombinant Yellow Fever 17D vaccine expressing Lassa virus glycoproteins.

  2006cited by this paper
• Identification of Protective Lassa Virus Epitopes That Are Restricted by HLA-A2

  2006cited by this paper
• Author Contributions: Please see

  2005cited by this paper
• A Live Attenuated Vaccine for Lassa Fever Made by Reassortment of Lassa and Mopeia Viruses

  2005cited by this paper
• Lassa Virus Infection of Human Dendritic Cells and Macrophages Is Productive but Fails to Activate Cells1

  2004cited by this paper
• Cells Expressing the RING Finger Z Protein Are Resistant to Arenavirus Infection

  2004cited by this paper
• Cutting Edge: Impairment of Dendritic Cells and Adaptive Immunity by Ebola and Lassa Viruses1

  2003cited by this paper
• Individual and Bivalent Vaccines Based on Alphavirus Replicons Protect Guinea Pigs against Infection with Lassa and Ebola Viruses

  2001cited by this paper
• A new mathematical model for relative quantification in real-time RT-PCR.

  2001cited by this paper
• Murine immune responses to mucosally delivered Salmonella expressing Lassa fever virus nucleoprotein.

  2000cited by this paper
• Effective Vaccine for Lassa Fever

  2000cited by this paper
• Antigenic relatedness between arenaviruses defined at the epitope level by monoclonal antibodies.

  1991cited by this paper
• Protection of guinea pigs from Lassa fever by vaccinia virus recombinants expressing the nucleoprotein or the envelope glycoproteins of Lassa virus.

  1989cited by this paper
• Construction of a recombinant vaccinia virus expressing the Lassa virus glycoprotein gene and protection of guinea pigs from a lethal Lassa virus infection.

  1988cited by this paper
• A case-control study of the clinical diagnosis and course of Lassa fever.

  1987cited by this paper
• A prospective study of the epidemiology and ecology of Lassa fever.

  1987cited by this paper
• Vaccinia recombinant expressing Lassa-virus internal nucleocapsid protein protects guineapigs against Lassa fever.

  1987cited by this paper
• Protection of lassa virus‐infected guinea pigs with lassa‐immune plasma of guinea pig, primate, and human origin

  1983cited by this paper
• Pathogenesis of Lassa virus infection in guinea pigs

  1982cited by this paper
• Lassa fever in the Eastern Province of Sierra Leone, 1970-1972. I. Epidemiologic studies.

  1974cited by this paper
• Lassa fever in the Eastern Province of Sierra Leone, 1970-1972. II. Clinical observations and virological studies on selected hospital cases.

  1974cited by this paper
• Lassa Virus Isolation from Mastomys natalensis Rodents during an Epidemic in Sierra Leone

  1974cited by this paper
• Lassa fever, a new virus disease of man from West Africa. II. Report of a laboratory-acquired infection treated with plasma from a person recently recovered from the disease.

  1970cited by this paper
• Lassa fever, a new virus disease of man from West Africa. IV. Electron microscopy of Vero cell cultures infected with Lassa virus.

  1970cited by this paper
• Lassa fever, a new virus disease of man from West Africa. I. Clinical description and pathological findings.

  1970cited by this paper

• Structure-guided design of a prefusion GPC trimer induces neutralizing responses against LASV

  2025cites this paper
• Nipah virus-derived defective interfering particles generated using non-infectious viral replicon particles confer protective efficacy comparable to those produced with standard full-length infectious virus.

  2025cites this paper
• Efficacy, safety, and immunogenicity of Lassa fever vaccines: A living systematic review and landscape analysis of vaccine candidates

  2025cites this paper
• Durable humoral immunity and long-term protection induced by a Crimean-Congo hemorrhagic fever virus replicon particle vaccine in mice

  2025cites this paper
• De novo rescue of new henipaviruses under BSL-4 conditions - From sequence to pathogen.

  2025cites this paper
• Replicon RNA vaccines: design, delivery, and immunogenicity in infectious diseases and cancer

  2025cites this paper
• Meeting Report of the 37th International Conference on Antiviral Research in Gold Coast, Australia, May 20-24, 2024, organized by the International Society for Antiviral Research.

  2024cites this paper
• Crimean-Congo hemorrhagic fever virus replicon particle vaccine is safe and elicits functional, non-neutralizing anti-nucleoprotein antibodies and T cell activation in rhesus macaques.

  2024cites this paper
• Delayed low-dose oral administration of 4'-fluorouridine inhibits pathogenic arenaviruses in animal models of lethal disease.

  2024cites this paper
• A novel BSL-2 Lassa virus reverse genetics system modelling the complete viral life cycle

  2024cites this paper
• Single-dose mucosal replicon-particle vaccine protects against lethal Nipah virus infection up to 3 days after vaccination

  2023cites this paper
• A Lassa virus mRNA vaccine confers protection but does not require neutralizing antibody in a guinea pig model of infection

  2023cites this paper
• Immunogenesis in Lassa fever and prospects for vaccine development

  2023cites this paper
• Lassa virus replicon particle vaccine protects strain 13/N guinea pigs against challenge with geographically and genetically diverse viral strains.

  2022cites this paper
• Lassa Virus Infection: a Summary for Clinicians.

  2022cites this paper
• Saltatory axonal conduction in the avian retina

  2022influential citation
• PROSPECTS OF LASSA FEVER CANDIDATE VACCINES

  2022cites this paper
• Обзор кандидатных вакцин для профилактики лихорадки Review of candidate vaccines for the prevention of Lassa fever

  2021cites this paper
• Viral replicon particles protect IFNAR-/- mice against lethal Crimean-Congo hemorrhagic fever virus challenge three days after vaccination.

  2021cites this paper
• Vaccines for Emerging Viruses—A Comprehensive Update

  2021cites this paper
• ChAdOx1-vectored Lassa fever vaccine elicits a robust cellular and humoral immune response and protects guinea pigs against lethal Lassa virus challenge

  2021cites this paper
• [Review of candidate vaccines for the prevention of Lassa fever].

  2021cites this paper
• ChAdOx1-vectored Lassa fever vaccine elicits a robust cellular and humoral immune response and protects guinea pigs against lethal Lassa virus challenge

  2021cites this paper
• Reverse genetics approaches for the development of bunyavirus vaccines.

  2020cites this paper
• Lassa Virus Genetics.

  2020cites this paper
• The Potential of Self-amplifying RNA Vaccines for Infectious Diseases and COVID-19

  2020cites this paper
• Lassa virus antigen distribution and inflammation in the ear of infected strain 13/N guinea pigs.

  2020cites this paper
• Prothrombin Time, Activated Partial Thromboplastin Time, and Fibrinogen Reference Intervals for Inbred Strain 13/N Guinea Pigs (Cavia porcellus) and Validation of Low Volume Sample Analysis

  2020cites this paper
• Self-Amplifying RNA Viruses as RNA Vaccines

  2020cites this paper
• Application of Viral Vectors for Vaccine Development with a Special Emphasis on COVID-19

  2020cites this paper
• Intervals for Inbred Strain 13 / N Guinea Pigs ( Cavia porcellus )

  2019cites this paper
• Lassa Virus Targeting of Anterior Uvea and Endothelium of Cornea and Conjunctiva in Eye of Guinea Pig Model

  2019cites this paper
• Diagnostics for Lassa fever virus: a genetically diverse pathogen found in low-resource settings

  2019cites this paper
• Vaccines inducing immunity to Lassa virus glycoprotein and nucleoprotein protect macaques after a single shot

  2019cites this paper
• Animal models for Lassa virus infection.

  2019cites this paper
• Protection from lethal Lassa disease can be achieved both before and after virus exposure by administration of single-cycle replicating Lassa virus replicon particles.

  2019cites this paper
• Hematology and Clinical Chemistry Reference Intervals for Inbred Strain 13/n Guinea Pigs (Cavia Porcellus ).

  2019cites this paper
• Emerging viruses and current strategies for vaccine intervention

  2019cites this paper
• Self-Replicating RNA Viruses for RNA Therapeutics

  2018cites this paper
• Will a Single-Cycle Adenovirus Vaccine Be Effective Against Ebola Virus?

  2018cites this paper